2022 World Conference on Lung Cancer (ePosters)-EP07.03-004. Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma

Pdf Summary

This study retrospectively reviewed data on patients with advanced and recurrent thymic carcinoma who received thoracic radiotherapy for local control between June 2005 and October 2021. The researchers calculated progression-free survival (PFS) and overall survival (OS) from the start of radiotherapy. They used Fine-Gray competing risk models to assess local progression and local progression-free death. The median follow-up time was 41 months. <br /><br />Overall, the study found that thoracic radiotherapy for local progression in advanced thymic carcinoma can achieve good local control and lead to good survival. Among the 46 patients who received chemotherapy and radiotherapy in the mediastinal region, the median PFS was 12.6 months and the median OS was not reached. <br /><br />Out of the 14 patients who had only local progression after systemic chemotherapy or surgery, the median duration of local progression after radiotherapy was not reached. Nine of these patients had recurrence after radiation, with three having recurrence only in the radiation field. The subsequent treatments for recurrence included chemotherapy, palliative radiation, and surgery. <br /><br />There were no adverse events related to thoracic radiotherapy, such as radiation pneumonia or heart disease. The Swimmer's plot visualizes the cumulative incidence of local progression and local progression-free death. <br /><br />In conclusion, this study suggests that thoracic radiotherapy is effective in achieving local control and improving survival in advanced thymic carcinoma with only local progression. However, further research is needed to validate these findings and assess long-term outcomes. The study has no conflicts of interest to disclose.

Asset Subtitle

Mao Uematsu

Meta Tag

Speaker Mao Uematsu

Topic Mesothelioma, Thymoma, and Other Thoracic Malignancies - Thymoma

Keywords

thymic carcinoma

thoracic radiotherapy

local control

progression-free survival

overall survival

Fine-Gray competing risk models

chemotherapy

mediastinal region

recurrence

adverse events